“We are pleased with the FDA’s decision to allow our planned clinical trial of GRNOPC1 in spinal cord injury to proceed,” said Thomas B. Okarma, Ph.D., M.D., Geron’s president and CEO. “Our goals for the application of GRNOPC1 in subacute spinal cord injury are unchanged – to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient’s injured spinal cord. Additionally, we are now formally exploring the utility of GRNOPC1 in other degenerative CNS disorders including Alzheimer’s, multiple sclerosis and Canavan disease.”
As Randy Marsh would say “I LOVE THE FUTURE!!!”
OMFG I LOVE BEING ALIVE NOW!! We can do, and are going to be able to do, the COOLEST STUFF! This is the road to curing spinal cord injuries. AHHHHHHHHH!!!
Now, if I only had my goddamn hover-car…